HKEX: 9887
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
View original source (HKEXnews)
Earlier from Nanjing Leads Biolabs Co., Ltd. Class H
- Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
- Voluntary announcement lbl-024 (opamtistomig, pd-l1/4-1bb bispecific antibody) granted orphan drug designation in japan
- Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
- WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC